Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).

Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Oluwole OO, Yakoub-Agha I, Khanal R, Rosenblatt J, Korn R, Peng W, Lui C, Wulff J, Shen R, Poddar S, Jung AS, Miao H, Beygi S, Jacobson CA

Open source

DOI: 10.1182/blood.2023021243
Published: 2024 Feb 8
Container: Blood
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/blood.2023021243,
  title = {Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).},
  author = {Neelapu SS and Chavez JC and Sehgal AR and Epperla N and Ulrickson M and Bachy E and Munshi PN and Casulo C and Maloney DG and de Vos S and Reshef R and Leslie LA and Oluwole OO and Yakoub-Agha I and Khanal R and Rosenblatt J and Korn R and Peng W and Lui C and Wulff J and Shen R and Poddar S and Jung AS and Miao H and Beygi S and Jacobson CA},
  year = {2024},
  journal = {Blood},
  doi = {10.1182/blood.2023021243},
  url = {https://doi.org/10.1182/blood.2023021243}
}

RIS

TY  - JOUR
TI  - Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
AU  - Neelapu SS
AU  - Chavez JC
AU  - Sehgal AR
AU  - Epperla N
AU  - Ulrickson M
AU  - Bachy E
AU  - Munshi PN
AU  - Casulo C
AU  - Maloney DG
AU  - de Vos S
AU  - Reshef R
AU  - Leslie LA
AU  - Oluwole OO
AU  - Yakoub-Agha I
AU  - Khanal R
AU  - Rosenblatt J
AU  - Korn R
AU  - Peng W
AU  - Lui C
AU  - Wulff J
AU  - Shen R
AU  - Poddar S
AU  - Jung AS
AU  - Miao H
AU  - Beygi S
AU  - Jacobson CA
PY  - 2024
JO  - Blood
DO  - 10.1182/blood.2023021243
UR  - https://doi.org/10.1182/blood.2023021243
ER  -

APA

SS, N., JC, C., AR, S., N, E., M, U., E, B., PN, M., C, C., DG, M., S, D. V., R, R., LA, L., OO, O., I, Y., R, K., J, R., R, K., W, P., C, L., J, W., R, S., S, P., AS, J., H, M., S, B., & CA, J. (2024). Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).. Blood. https://doi.org/10.1182/blood.2023021243

Source records

pubmed · retrieved 2026-09-25T16:50:56.858Z
europe-pmc · retrieved 2026-09-25T16:50:56.864Z
hal · retrieved 2026-09-25T16:50:56.899Z